HER2-targeted therapy active in amplified but not mutated tumors Skip to content The CRC Digest HER2-targeted therapy active in amplified but not mutated tumors Tucatinib and trastuzumab achieved responses in 38% of HER2-amplified cancers but only 6% of HER2-mutated cases, suggesting amplification status may better predict benefit from this combination. (NPJ Precis Oncol) This content is informational only and
Liver-only metastases show lower KRAS mutation prevalence Skip to content The CRC Digest Liver-only metastases show lower KRAS mutation prevalence Patients with permanently liver-limited disease had significantly lower KRAS mutation rates compared to those with extrahepatic or mixed metastatic patterns. (ESMO Gastrointest Oncol) This content is informational only and does not constitute medical advice. Always consult your
Nationwide study finds stage, not biology, drives early-onset CRC outcomes Skip to content The CRC Digest Nationwide study finds stage, not biology, drives early-onset CRC outcomes Among 80,551 Dutch patients, those under 50 more often presented with stage III or IV disease and left-sided or rectal tumors, but after accounting for these factors, survival matched that of 50–69
Early tumor shrinkage predicts longer survival in metastatic CRC on intensive chemotherapy Skip to content The CRC Digest ◆ TRIAL DATA Early tumor shrinkage predicts longer survival in metastatic CRC on intensive chemotherapy In 72 Vietnamese patients treated with first-line mFOLFOXIRI plus bevacizumab, 57% achieved early tumor shrinkage (≥20% reduction at 8 weeks), which was associated with greater depth of response and significantly
Tucatinib plus trastuzumab shows 38% response in HER2-amplified cancers Skip to content The CRC Digest ▸ TREATMENT Tucatinib plus trastuzumab shows 38% response in HER2-amplified cancers A phase II trial of 32 patients with HER2 alterations found a 38% response rate in HER2-amplified tumors (including one KRAS co-mutated colon cancer) and 6% in HER2-mutated cancers, with median progression-free survival of
Early-onset CRC survival gap tied to later-stage diagnosis, not distinct biology Skip to content The CRC Digest ♥ LIVING WITH CRC Early-onset CRC survival gap tied to later-stage diagnosis, not distinct biology Analysis of 80,551 Dutch patients showed that poorer crude survival in under-50 CRC patients was largely explained by more advanced disease at diagnosis; after matching for stage and treatment,
Liver-limited metastatic CRC shows distinct biology with lower KRAS mutation rates Skip to content The CRC Digest ◇ RESEARCH Liver-limited metastatic CRC shows distinct biology with lower KRAS mutation rates A Netherlands study of 1,026 patients found that 20% had metastases permanently confined to the liver, with lower KRAS mutation frequency and more synchronous presentation compared to other metastatic patterns. (ESMO
Young-onset CRC mortality rises fastest in Western US, with Southern states showing highest rates Skip to content The CRC Digest Young-onset CRC mortality rises fastest in Western US, with Southern states showing highest rates Among people aged 15-49 in the US, colorectal cancer mortality increased at a mean annual rate of 1.06% from 2014-2023, with more than twofold variation across states; Alaska, Kentucky,
Blood biomarker hPG80 shows promise for CRC screening and treatment monitoring Skip to content The CRC Digest ▪ SCREENING Blood biomarker hPG80 shows promise for CRC screening and treatment monitoring A scoping review of five studies encompassing 2,692 participants found that plasma hPG80 was significantly overexpressed in CRC patients compared to controls and decreased significantly after surgery, though optimal thresholds and
IgA antibody suppresses colon cell proliferation and tumor formation in mice Skip to content The CRC Digest ◇ RESEARCH IgA antibody suppresses colon cell proliferation and tumor formation in mice Preclinical experiments in mice found that IgA deficiency increased susceptibility to colorectal cancer models; oral IgA treatment reduced epithelial proliferation and protected against tumors through interaction with the surface protein DMBT1. (Nature)
Bacterial signature test after positive FIT reduces colonoscopies but misses some cancers Skip to content The CRC Digest ▪ SCREENING Bacterial signature test after positive FIT reduces colonoscopies but misses some cancers Among 1,291 participants with positive FIT in a Galician screening program, the RAID-CRC Screen bacterial test would have avoided 15.8% of colonoscopies while missing two CRCs and 55 advanced
Antibiotic plus immunotherapy combination shows activity in F. nucleatum-positive MSS metastatic CRC Skip to content The CRC Digest ◆ TRIAL DATA Antibiotic plus immunotherapy combination shows activity in F. nucleatum-positive MSS metastatic CRC A multicenter phase 2 trial of 33 patients with Fusobacterium nucleatum-positive, microsatellite-stable metastatic CRC treated with tislelizumab, fruquintinib, and metronidazole achieved a median progression-free survival of 6.0 months, with
Positive stool DNA test still yields advanced neoplasia in one in five patients with a prior normal colonoscopy Skip to content The CRC Digest ▪ SCREENING Positive stool DNA test still yields advanced neoplasia in one in five patients with a prior normal colonoscopy — Clinical and Translational Gastroenterology A registry-based analysis from the New Hampshire Colonoscopy Registry compared colonoscopy outcomes after positive multitarget stool DNA (mt-sDNA) tests in 739
Phase III trial shows survival benefit for tyrosine kinase inhibitor plus immunotherapy in pretreated microsatellite-stable colorectal cancer Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial shows survival benefit for tyrosine kinase inhibitor plus immunotherapy in pretreated microsatellite-stable colorectal cancer — ESMO Gastrointestinal Oncology The interim analysis of the phase III STELLAR-303 trial demonstrated an overall survival benefit with the combination of zanzalintinib (a tyrosine kinase
Silencing DNA repair genes with nanoparticles restores immune response in microsatellite-stable colorectal cancer Skip to content The CRC Digest ◇ RESEARCH Silencing DNA repair genes with nanoparticles restores immune response in microsatellite-stable colorectal cancer — Molecular Cancer Microsatellite-stable (MSS) colorectal cancer, which represents the majority of cases, typically does not respond to immunotherapy because it has a low tumor mutational burden. Researchers developed lipid nanoparticles
Gut bacteria engineered to convert cholesterol into a tumor-suppressing metabolite show promise in preclinical colorectal cancer models Skip to content The CRC Digest ◇ RESEARCH Gut bacteria engineered to convert cholesterol into a tumor-suppressing metabolite show promise in preclinical colorectal cancer models — Nature: Colorectal Cancer Researchers identified a cholesterol metabolite called 4-cholesten-3-one (4-C-3) that is depleted in colorectal cancer and can suppress tumor growth by blocking EGFR (epidermal